Results
1 -
10 of
118Gao Jiadi, Fang Cheng, Xiao Zhiyan, Huang Li, Chen Chin-Ho, Wang Li-Ting, Lee Kuo-Hsiung.
Discovery of novel 5-fluoro-N2,N4-diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9, Med. Chem. Commun., 2015 A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol, Cancer Chemotherapy and Pharmacology Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents, Cancer Chemotherapy and Pharmacology Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review, Annals of Hematology Fusarium proliferatum, an endophytic fungus from Dysoxylum binectariferum Hook.f, produces rohitukine, a chromane alkaloid possessing anti-cancer activity, Antonie van Leeuwenhoek The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells, Journal of Neuro-Oncology Synthetic Cyclin Dependent Kinase Inhibitors, Drug Resistance in Leukemia and Lymphoma III The CDK inhibitors in cancer research and therapy, Journal of Cancer Research and Clinical Oncology Cell Cycle Activation and Spinal Cord Injury, Neurotherapeutics Small-Molecule Inhibitors of Cyclin-Dependent Kinases: Molecular Tools and Potential Therapeutics, Cyclin Dependent Kinase (CDK) Inhibitors